Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

13 December 2024

Alphamab Oncology Presented the Phase II Clinical Data of KN046 in Combination with Axitinib for the Treatment of Advanced NSCLC at ESMO IO Congress 2024 Results from Cohort A (previously untreated and PD-L1 TPS≥1%) and cohort B (progressed on CPIs) were reported at this ESMO IO Congress
25 November 2024

Differentiated Innovation Strength Highly Recognized, Alphamab Oncology Featured on Multiple Annual Rankings developing differentiated, clinically valuable and globally competitive new drugs
11 November 2024

Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024 JSKN033 presented a favorable safety profile and encouraging anti-cancer activity in heavily treated patients.
17 October 2024

IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved as neoadjuvant treatment for HER2-positive early or locally advanced breast cancer.
30 September 2024

Alphamab Oncology and CSPC Achieved a Licensing Agreement on Anti-HER2 Bispecific ADC JSKN003 in Mainland China the Company is entitled to receive upfront payment and milestone payments of up to RMB 3.08 billion in total,and is also entitled to receive a double-digit percentage of royalties on net product sales...
16 September 2024

Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Both were pooled analysis of two phase I clinical studies of JSKN003 conducted in Australia and China on platinum-resistant ovarian cancer and advanced HER2-positive (IHC 3+) solid tumors.
16 August 2024

Alphamab Oncology Reports 2024 Interim Results and Business Highlights 2024 Interim Results and Business Highlights
12 August 2024

Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Onsite Poster display date: Saturday, 14 September 2024
06 June 2024

Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products Alphamab and ArriVent will collaborate to use Alphamab's proprietary linker-payload (Alphatecan) and glycan-conjugation platforms to discover and develop novel ADCs
03 June 2024

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dos...